Effects of Xiangshao Granules on Anxiety in Menopausal Women.

Inclusion Criteria:

• meet the diagnostic criteria for menopause syndrome (age 40-65 years, being in themenopausal transition stage or postmenopausal stage determined according to the 2011Stages of Reproductive Aging Workshop +10 criteria).
• 50 ≤ SAS scores ≤ 69.
• improved Kupperman scores ≥16.
• has an intact uterus and at least one ovary.
• able and willing to participate in study and provide written informed consent, andagrees to follow all study requirements. The investigator consider the subject able tocomplete the study.

Exclusion Criteria:

• history of allergy or sensitivity to investigational product.
• currently or historically taking medication or psychotherapy for menopause anxiety inthe past 4 weeks, including but not limited to estrogens, oestrogen-like hormone,Chinese medicine or health care products used to relieve anxiety (such as soyisoflavones, vitamin E, black cohosh), anti-anxiety agents, antidepressants, moodstabilizers, sedatives.
• anxiety or other psychiatric disease unrelated to menopause (eg., currently orpreviously diagnosed as major depression, acute panic disorder, obsessive-compulsivedisorder, phobia, hypochondria, mood disorder or schizophrenia or psychiatric diseasescaused by other psychoactive substances or organic diseases), anxiety symptoms causedby stress, suicidal tendency, alcohol or drug dependence, etc.
• having major depression as defined by a SDS score≥70 at screening.
• systemic disease (eg., hypothyroidism/hyperthyroidism, unstable coronary heartdisease, severe hypertension [sbp≥180mmHg and/or dbp≥110mmHg] or pheochromocytoma).
• definite diagnosis of endometrial cancer, cervical cancer, ovarian cancer and othergynecological malignancies, as well as breast cancer.
• severe liver or kidney diseases (eg., alanine aminotransferase[ALT]/aspartateaminotransferase[AST]/serum creatinine[Scr] levels 2 times greater than the upperlimit of normal) or severe primary diseases in cardiovascular, cerebrovascular, liver,kidney and hematopoietic system.
• participated in other clinical trials within the last 3 months.
• lactating or pregnant women, or plan to become pregnant during study or not agree touse reliable contraceptive methods throughout the study period.
• other reasons the investigator consider the patient may not be suitable for the study.